Every so often a science story crosses my desk that makes me stop and actually smile at my screen, and this week it was news out of Yahoo that Daraxonrasib, the targeted drug that made headlines for pancreatic cancer, may also help some patients with lung cancer.

Let me back up for a second, because I remember when a cancer diagnosis meant essentially one treatment plan for everybody. You got surgery, or chemotherapy, or radiation, and everyone got more or less the same playbook no matter what was happening inside their particular tumor. It was blunt. It was the best we had. My aunt went through exactly that in the late 80s and I still remember how helpless the whole family felt watching it.

Targeted therapies changed all that. Instead of attacking every fast-dividing cell in the body, drugs like Daraxonrasib go after a specific genetic mutation that's driving the cancer. Daraxonrasib targets KRAS mutations, which is a big deal because KRAS was considered "undruggable" for decades. Scientists knew about the problem since the early 80s, right around when I was watching Steve Jobs pull that first Macintosh out of a bag, and for most of my adult life the answer was a shrug. Then researchers finally found the pocket in the protein where a drug could latch on, and everything changed.

The pancreatic cancer results earlier this year were remarkable on their own. Pancreatic cancer is one of the hardest diagnoses there is, usually caught late, usually stubbornly resistant to treatment. So when a drug shows real response rates in that population, oncologists pay attention.

Now new trial results suggest the same drug might benefit a subset of lung cancer patients whose tumors carry the relevant mutation. And I want to emphasize that word, subset, because this is not a cure for lung cancer broadly. It's for people whose cancer has that specific genetic signature, which is exactly how modern oncology is supposed to work. You test the tumor, you find the mutation, you match the drug to it.

It reminds me of how computing evolved, if you'll indulge me for a moment. We went from mainframes that did one thing for everyone to personal machines tailored to the person sitting in front of them. Cancer treatment is going through the same quiet revolution, one mutation at a time. My colleague Marcus could explain the molecular mechanics far better than I ever could, and his deep-dives on drug development are well worth your time if you want the under-the-hood version.

So what should you take away from this if lung cancer touches your family? Talk to an oncologist about genetic testing of the tumor, sometimes called biomarker testing or molecular profiling. It's become standard practice at major cancer centers, but not every patient gets it automatically, and knowing whether a mutation like KRAS is present can open doors to trials and treatments that simply weren't options five years ago.

The results are still early, I want to be clear about that. Trials take time, and the road from promising data to approved treatment is long and deliberately careful, because it should be. But every time a drug built for one cancer turns out to work on another, thousands more patients suddenly have a new thread of hope to pull on.

I've watched long enough to know that incremental is how real progress usually arrives. Not with a bang, but with a trial result that quietly widens the circle of who can be helped. I'll be following this one, and I'll report back when we hear more about the larger trials.